Company News Summary | 31 Jan 2018

Click the print icon in your browser to print this report. Currency is in AUD unless otherwise specified

Starpharma Holdings Announces to Commence DEP Cabazitaxel Phase 1/2 Trial

11:09:00 | Associate analysts

Original annuncemenet:Starpharma to commence DEP cabazitaxel phase 1/2 trial

Starpharma Holdings announced that it has received regulatory and ethics approvals to commence its phase 1/2 clinical trial for DEP cabazitaxel. The objectives of the trial are to evaluate the safety, tolerability and pharmacokinetics of DEP cabazitaxel, to define a recommended phase 2 dose (RP2D), and then to determine anti-tumour efficacy of the product in select tumour types. The trial will be conducted at multiple sites, with Guy's Hospital London and University College London Hospital (UCLH) in the UK being the first sites to open for recruitment. Further sites will open and commence recruitment as dose escalation progresses and the phase 2 part of the trial gets underway. 35 patients will be enrolled across the phase 1/2 trial.

This report appeared on 2021 Morningstar Australasia Pty Limited

© Copyright 2021 Morningstar Australasia Pty Ltd ABN: 95 090 665 544 ("Morningstar"), AFSL no 240892. (a subsidiary of Morningstar, Inc.). This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written content of Morningstar. Some of the material provided is published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO").

DISCLAIMER: To the extent that any of the content above constitutes advice, it is general advice that has been prepared without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain appropriate financial, legal and taxation advice before making any financial investment decision. If applicable, investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Please refer to our Financial Services Guide (FSG) for more information at FSG or phone Morningstar on 1800 03 44 55 to request a copy. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for any use or distribution of any of this information

DISCLOSURE: Employees may have an interest in the securities discussed in this report.